Prasad Sanjay Dhiwar

Dr. Prasad Sanjay Dhiwar

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2021 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
GMGurubasavaraj Swamy Purawarga Matada
Gurubasavaraj Swamy Purawarga Matada
PDPrasad Sanjay Dhiwar
Prasad Sanjay Dhiwar
NANahid Abbas
Nahid Abbas
ESEkta Singh
Ekta Singh
AGAbhishek Ghara
Abhishek Ghara
SBSapna Vyas Bhargava
Sapna Vyas Bhargava
Breast cancer (BC) is a second common malignancy in female globally. Hence, identification of novel therapeutic agents is extremely important. Molecular docking and MD simulation are the important tools in the process of drug discovery for searching the potential hits. The structure-based drug designing technique also reveals the information about ligands behavior in computational environment. Docking tools help in visualization and analysis of protein–ligand complex at atomic level. Molecular dynamics shows the stability of the molecules in the receptor cavity in the simulated environment. In this research work, we have screened potent phytochemicals against the BC. We docked the phytochemicals and examined the binding affinities of ligands towards the EGFR, HER2, estrogen and NF-κB receptors. Pristimerin, ixocarpalactone A, viscosalactone B and zhankuic acid A have shown higher binding affinities and energies towards targeted receptors among the screened phytochemicals. MD simulation study shows stability of docked complex for pristimerin and HER2 receptor. These phytochemicals can be repurposed for their anticancer activity. This in-silico work provides a strong ground for further investigation of their anticancer activity. Graphical Abstract Communicated by Ramaswamy H. Sarma

1 May 2021 in Anti-Cancer Agents in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
NANahid Abbas
Nahid Abbas
GMGurubasavaraja S.P. Matada
Gurubasavaraja S.P. Matada
PDPrasad Sanjay Dhiwar
Prasad Sanjay Dhiwar
SPShilpa Patel
Shilpa Patel
GDGiles Devasahayam
Giles Devasahayam
The rationale behind drug design is the strategic utilization of heterocyclic fragments with specific physicochemical properties to form molecular targeted agents. Among the heterocyclic molecules, pyrimidine has proved to be a privileged pharmacophore for various biological cancer targets. The anti-cancer potential of small molecules with fused and substituted pyrimidines can be enhanced through bioisosteric replacements and altering their ADME parameters. Although several small molecules are used in cancer chemotherapy, oncology therapeutics has various limitations, especially in their routes of administration and their concurrent side effects. Such pernicious effects may be overcome, via selective biological targeting. In this review, the biological targets, to inhibit cancer, have been discussed. The structural activity relationship of fused and substituted pyrimidines was studied. Eco-friendly synthetic approaches for pyrimidine derivatives have also been discussed. This review will give an insight to scientists and researchers of medicinal chemistry discipline to design small molecules having a pyrimidine scaffold with high anti-cancer potential.

9 May 2023 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
PDPrasad Sanjay Dhiwar
Prasad Sanjay Dhiwar
GMGurubasavaraja Swamy Purawarga Matada
Gurubasavaraja Swamy Purawarga Matada
RPROHIT PAL
ROHIT PAL
ESEkta Singh
Ekta Singh
AGAbhishek Ghara
Abhishek Ghara
GAGanesh Andhale
Ganesh Andhale
Epidermal growth factor receptor (EGFR) and its subtype human epidermal growth factor receptor 2 (HER2) gets activated when its endogenous ligand(s) bind to its ATP binding site of target receptors. In breast cancer (BC), EGFR and HER2 are two proteins are overexpressed which leads to overexpression of cells proliferation and decreases cell death/apoptosis. Pyrimidine is one of the most widely studied heterocyclic scaffolds for EGFR as well as HER2 inhibition. We gather some remarkable results for fused-pyrimidine derivatives on various cancerous cell lines (in-vitro) and animal (in-vivo) evaluation to highlight their potency. The heterocyclic (five, six-membered, etc.) moieties which are coupled with pyrimidine moiety are potent against EGFR and HER2 inhibitions. Hence structure-activity relationship (SAR) plays important role in study of heterocyclic moiety along pyrimidine and effects of substituents, groups for increase or decrease in the cancerous activity and toxicity. By thoughtful of fused pyrimidines SAR study, it facilitates in receiving excellent overview of the compounds by concerning of efficacy and potential summary for future EGFR inhibitors. Furthermore, we studied the in-silico interactions of synthesized compounds to evaluate binding affinity towards the key amino acids.. Communicated by Ramaswamy H. Sarma

10 July 2023 in ChemistrySelect
Verified
Journal Article
Closed access
RPROHIT PAL
ROHIT PAL
GTGhanshyam Teli
Ghanshyam Teli
GMGurubasavaraja Swamy Purawarga Matada
Gurubasavaraja Swamy Purawarga Matada
PDPrasad Sanjay Dhiwar
Prasad Sanjay Dhiwar

9 August 2021 in Inflammopharmacology
Verified
Journal Article
Closed access
PDF file
ESEkta Singh
Ekta Singh
GMGurubasavaraja Swamy Purawarga Matada
Gurubasavaraja Swamy Purawarga Matada
NANahid Abbas
Nahid Abbas
PDPrasad Sanjay Dhiwar
Prasad Sanjay Dhiwar
AGAbhishek Ghara
Abhishek Ghara
ADArka Das
Arka Das

5 February 2022 in Journal of Molecular Structure
Verified
Journal Article
Closed access
GMGurubasavaraja Swamy Purwarga Matada
Gurubasavaraja Swamy Purwarga Matada
PDPrasad Sanjay Dhiwar
Prasad Sanjay Dhiwar
NANahid Abbas
Nahid Abbas
ESEkta Singh
Ekta Singh
AGAbhishek Ghara
Abhishek Ghara
NRNulgumnalli Manjunathaiah Raghavendra
Nulgumnalli Manjunathaiah Raghavendra